All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your GvHD Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.

Brought to you by

Scientific Education Support logo
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2023-10-20T11:08:37.000Z

Visual abstract | A phase II trial of CD24Fc for GvHD prophylaxis

By Ella Dixon, Louise Niven
Oct 20, 2023
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in GvHD.

The GvHD Hub is pleased to present a visual abstract representing data from a phase II trial (NCT02663622) evaluating CD24Fc, a novel CD24 fusion protein, for graft-versus-host disease prophylaxis.1

This study, which was conducted in two parts (a double-blind dose-escalation phase and an open-label extension phase), evaluated the safety, recommended dose, and efficacy of CD24Fc in patients undergoing allogeneic hematopoietic stem cell transplantation.1 Overall, CD24Fc demonstrated improved graft-versus-host disease-free survival compared with matched controls, and no patients experienced dose-limiting toxicities.1


 

Visual abstract

To download this visual abstract, click below.

Download here

  1. Magenau J, Jaglowski S, Uberti J, et al. A phase 2 trial of CD24Fc for prevention of graft-vs-host disease. Blood. 2023. Online ahead of print. DOI: 1182/blood.2023020250

More about...
CD24FcGraft-versus-host diseaseVisual abstracts

Your opinion matters

After reading this article, I commit to reviewing the latest data on ECP for cGvHD, and apply my learnings to guide my management of patients with cGvHD in clinical practice.
5 votes - 72 days left ...

Related articles

Add bookmark

Visual abstract | Ruxolitinib versus basiliximab in adult patients with steroid-refractory aGvHD

The current recommended second-line treatment for SR-aGvHD is ruxolitinib, with basiliximab also considered a feasible salvage therapy option. Here, we...

Dec 8, 2023
Add bookmark

Visual abstract | Ruxolitinib versus basiliximab in adult patients with steroid-refractory aGvHD

The current recommended second-line treatment for SR-aGvHD is ruxolitinib, with basiliximab also...

Dec 8, 2023
Add bookmark

Visual abstract| Pooled allogeneic faecal microbiota therapy for steroid resistant GI-aGvHD

The GVHD Hub is proud to present a visual abstract summary of a multicenter phase II trial investigating the safety and efficacy of the pooled allogeneic...

Sep 19, 2023
Add bookmark

Visual abstract| Pooled allogeneic faecal microbiota therapy for steroid resistant GI-aGvHD

The GVHD Hub is proud to present a visual abstract summary of a multicenter phase II trial investigating the...

Sep 19, 2023
Add bookmark

Visual abstract | REACH5: Ruxolitinib in pediatric cGvHD

In REACH5, pediatric patients with treatment-naïve or SR-cGvHD were treated with ruxolitinib plus corticosteroids and spilt into 3 groups according to age.

Jul 25, 2023
Add bookmark

Visual abstract | REACH5: Ruxolitinib in pediatric cGvHD

In REACH5, pediatric patients with treatment-naïve or SR-cGvHD were treated with ruxolitinib plus corticosteroids and spilt into 3 groups...

Jul 25, 2023
Add bookmark

Visual abstract | Vitamin A for the prevention of GvHD in pediatric patients undergoing allo-HSCT

Here, we present data from a trial evaluating the efficacy of high-dose vitamin A in preventing GvHD in pediatric patients undergoing allo-HSCT...

Mar 20, 2023
Add bookmark

Visual abstract | Vitamin A for the prevention of GvHD in pediatric patients undergoing allo-HSCT

Here, we present data from a trial evaluating the efficacy of high-dose vitamin A in preventing GvHD...

Mar 20, 2023

Newsletter

Subscribe to get the best content related to GvHD delivered to your inbox